更新于：2024-09-21
Olanzapine
奥氮平
更新于：2024-09-21
概要
基本信息
简介Zyprexa® 或奥氮平（一种抗精神病药物）广泛用于治疗精神分裂症、双相1型障碍和伴随这些病症的激越。该药物由礼来研发的一种D1受体抑制剂，可有效调节大脑内多巴胺和血清素的水平。自从1996 年获得欧盟初步批准后，奥氮平已成为治疗各种精神障碍的首选药物。它在治疗此类疾病方面的功效已得到充分证明，使其成为精神疾病患者不可或缺的药物。 该药物在现代医学中发挥着重要的作用，因为它具有调节脑化学的能力，从而为与精神分裂症和双相情感障碍相关的经常失能的症状提供急需的缓解。 |
药物类型 小分子化药 |
别名 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine、mdc-TJK、Olanzapin + [35] |
作用机制 5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、5-HT2C receptor拮抗剂(5-羟色胺2C受体拮抗剂)、5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂) |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C17H20N4S |
InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N |
CAS号132539-06-1 |
关联
535
项与 奥氮平 相关的临床试验An Open-label, Two-arm, Multicenter, Phase II Randomized Controlled Trial Assessing the Impact of Olanzapine on the Efficacy of First-line Immunotherapy in Patients With Advanced EGFR Mutation-negative Non-small Cell Lung Cancer (NSCLC).
Randomized, Double-Blind Study of FOND (Fosaprepitant, ONdansetron, Dexamethasone) Plus Either Olanzapine 2.5 Mg Versus 5 Mg for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Conditioning: the FONDO-LOW Study
Olanzapine effects on chemotherapy regimen induced anxiety in pediatric patients with cancer: A randomized, double-blind, placebo-controlled clinical trial
100 项与 奥氮平 相关的临床结果
登录后查看更多信息
100 项与 奥氮平 相关的转化医学
登录后查看更多信息
100 项与 奥氮平 相关的专利（医药）
登录后查看更多信息
9,695
项与 奥氮平 相关的文献（医药）2025-01-01TALANTA
Fabrication of a molecularly imprinted polymer-based electrochemical sensor for the selective assay of antipsychotic drug clozapine and performance comparison with LC-MS/MS
Article
作者: Kaya, S. Irem ; Al, Selen ; Budak, Fatma ; Kul, Aykut ; Kaya, S Irem ; Cetinkaya, Ahmet ; Sagirli, Olcay ; Ozkan, Sibel A. ; Ozkan, Sibel A
Clozapine (CLO) is an atypical antipsychotic drug indicated for the treatment of schizophrenia. The treatment effectiveness of CLO is better than that of other atypical antipsychotics, and it has the advantage of being able to determine its effectiveness by measuring its concentration in the patient's blood. Thus, sensitive, selective, and accurate determination of CLO in blood is highly significant for treatment monitoring. This study describes the design and fabrication of a molecularly imprinted polymer (MIP)-based electrochemical sensor for CLO determination. This is the first MIP-based electrochemical application in the literature for CLO determination. Employing the thermal polymerization approach, the MIP was formed on the glassy carbon electrode (GCE) using CLO as the template, trans-3-(3-Pyridyl)acrylic acid (3,3-TA) as the functional monomer, and the support of zinc oxide nanoparticles (ZnO NPs). Elaborate characterizations in terms of surface morphology and electrochemistry were performed via scanning electron microscopy (SEM), cyclic voltammetry (CV), and electrochemical impedance spectroscopy (EIS) methods. An indirect approach was employed to determine CLO in standard solution, real human biological samples, and tablet formulation, using 5 × 10-3 M [Fe(CN)6]3-/4- solution as the redox probe. The limit of detection (LOD) values for the standard solution and serum sample were calculated as 2.9 × 10-11 M and 6.01 × 10-12 M, respectively. These values and recovery studies confirmed the sensor's sensitivity and feasibility. The measurements in the presence of similarly structured compounds (olanzapine and quetiapine fumarate) verified the sensor's superior selectivity. Moreover, the developed sensor's performance was compared and verified using an LC-MS/MS method using the student's t-test and F-test.
2024-12-01PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Adult and adolescent antipsychotic exposure increases delay discounting and diminishes behavioral flexibility in male C57BL/6 mice
Article
作者: Haste, D. Austin ; Newland, M Christopher ; Haste, D Austin ; Morrow, Carleigh ; Newland, M. Christopher ; Kendricks, Dalisa R. ; Kendricks, Dalisa R
Second-generation antipsychotics are frequently prescribed to adolescents, but the long-term consequences of their use remain understudied. These medications work via monoamine neurotransmitter systems, especially dopamine and serotonin, which undergo considerable development and pruning during adolescence. Dopamine and serotonin are linked to a wide host of behaviors, including impulsive choice and behavioral plasticity. In a murine model of adolescent antipsychotic use, male C57BL/6 mice were exposed to either 2.5 mg/kg/day risperidone or 5 mg/kg/day olanzapine via drinking water from postnatal days 22-60. To determine whether the adolescent period was uniquely sensitive to antipsychotic exposure, long-term effects on behavior were compared to an equivalently exposed group of adults where mice were exposed to 2.5 mg/kg risperidone from postnatal days 101-138. Motor activity and body weight in adolescent animals were assessed. Thirty days after exposure terminated animal's behavioral flexibility and impulsive choice were assessed using spatial discrimination reversal and delay discounting. Antipsychotic exposure produced a modest change in behavior flexibility during the second reversal. There was a robust and reproducible difference in impulsive choice: exposed animals devalued the delayed alternative reward substantially more than controls. This effect was observed both following adolescent and adult exposure, indicating that an irreversible change in impulsive choice occurs regardless of the age of exposure.
2024-12-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Integrated spectroscopic approaches for the facile one pot quantification of olanzapine in pharmaceutical formulation and spiked human plasma
Article
作者: Hamad, Ahmed Abdulhafez ; Madian, Huda ; Samir, Ebtihal ; Badr-Eldin, Khaled M ; Derayea, Sayed M
In this work, the xanthene dye, erythrosine B, was employed as a probe for the determination of olanzapine using two fast and highly simple analytical approaches. The assay was based on the formation of a binary complex between the drug and erythrosine B in a slightly acidic aqueous buffered solution. In the first method, the absorbance of the formed product was monitored at 558 nm. The reaction stoichiometry was investigated, and the stability constant of the formed complex was estimated. The linear range of the method that obeyed Beer's law was in the concentration range of 0.6-8.0 µg/ml. The calculated detection and quantitation limits were 0.2 and 0.6 µg/mL. Upon adding the drug solution to erythrosine B, the native fluorescence of the dye was quenched and monitored at 550 nm after excitation at 528 nm. Thus, the fluorescence quenching was utilized as the quantitative signal in the spectrofluorimetric approach. The extent of quenching in the fluorescence intensity was rectilinear with the drug concentration in a range of 0.1-2.5 µg/ml with a detection limit of 0.032 µg/ml. Both approaches were analytically validated based on the guiding rules of the ICH with acceptable results, and were utilized efficiently in the analysis of olanzapine in commercial tablets containing the cited drug. In addition, owing to its high sensitivity and selectivity, the spectrofluorimetric method was applied for drug analysis in spiked human plasma with satisfactory % recoveries. Finally, the greenness of the methods was confirmed using eco-score scale and Analytical Green Evaluation metrics.
100 项与 奥氮平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 恶心和呕吐 | 日本 | 2017-12-25 | |
| 躁动 | 美国 | 2009-03-19 | |
| 抑郁症 | 美国 | 2009-03-19 | |
| 难治性抑郁症 | 美国 | 2009-03-19 | |
| 双相情感障碍及相关疾病 | 中国 | 2006-01-01 | |
| 躁郁症1型 | 美国 | 1996-09-30 | |
| 躁郁症 | 欧盟 | 1996-09-27 | |
| 躁郁症 | 冰岛 | 1996-09-27 | |
| 躁郁症 | 列支敦士登 | 1996-09-27 | |
| 躁郁症 | 挪威 | 1996-09-27 | |
| 躁狂 | 欧盟 | 1996-09-27 | |
| 躁狂 | 冰岛 | 1996-09-27 | |
| 躁狂 | 列支敦士登 | 1996-09-27 | |
| 躁狂 | 挪威 | 1996-09-27 | |
| 精神分裂症 | 欧盟 | 1996-09-27 | |
| 精神分裂症 | 冰岛 | 1996-09-27 | |
| 精神分裂症 | 列支敦士登 | 1996-09-27 | |
| 精神分裂症 | 挪威 | 1996-09-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 化疗引起的恶心和呕吐 | 临床3期 | 中国 | 2020-10-01 | |
| 实体瘤 | 临床3期 | 中国 | 2020-10-01 | |
| 呕吐 | 临床3期 | 中国 | 2020-10-01 | |
| 抑郁 | 临床3期 | 中国 | 2007-08-01 | |
| 抑郁 | 临床3期 | 日本 | 2007-08-01 | |
| 抑郁 | 临床3期 | 韩国 | 2007-08-01 | |
| 病理性赌博症 | 临床3期 | 美国 | 2007-02-01 | |
| 体重增加 | 临床3期 | 美国 | 2006-11-01 | |
| 体重增加 | 临床3期 | 巴西 | 2006-11-01 | |
| 体重增加 | 临床3期 | 以色列 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 1,933 | 廠範窪範積餘鹽艱願築(鏇獵餘蓋網窪網餘遞艱) = 築製襯襯顧網顧淵製築 廠窪衊憲選製築願艱鑰 (簾糧糧廠鑰艱鑰齋憲窪 ) 更多 | 积极 | 2024-09-14 | ||
No Olanzapine | 廠範窪範積餘鹽艱願築(鏇獵餘蓋網窪網餘遞艱) = 壓窪襯顧艱積製窪蓋繭 廠窪衊憲選製築願艱鑰 (簾糧糧廠鑰艱鑰齋憲窪 ) 更多 | ||||||
临床3期 | 675 | TEV-'749 high dose | 顧鏇觸顧糧壓鏇齋觸鹹(獵鏇範範壓選範膚鏇憲) = 鬱顧構淵鑰觸鹽鹹願築 顧遞鑰鬱襯齋獵積鏇範 (獵醖願繭範選範糧餘鑰 ) 达到 | 积极 | 2024-05-08 | ||
TEV-'749 medium dose | 顧鏇觸顧糧壓鏇齋觸鹹(獵鏇範範壓選範膚鏇憲) = 鬱簾廠製構觸襯齋獵鑰 顧遞鑰鬱襯齋獵積鏇範 (獵醖願繭範選範糧餘鑰 ) 达到 | ||||||
临床3期 | 52 | 80 mg orally on Days 0 (Aprepitant) | 範壓廠願鑰醖繭窪鹽鏇(遞廠遞顧膚鹹衊淵蓋顧) = 鏇遞壓鏇鑰壓遞鑰鏇製 窪鑰鹹夢網獵顧衊糧範 (襯鹹壓網蓋積鹽廠憲積, 鹽壓憲築選襯窪顧壓醖 ~ 築觸願窪鏇遞積憲願築) 更多 | - | 2024-01-22 | ||
+2 (Olanzapine) | 範壓廠願鑰醖繭窪鹽鏇(遞廠遞顧膚鹹衊淵蓋顧) = 願範憲觸願艱鬱遞淵鹽 窪鑰鹹夢網獵顧衊糧範 (襯鹹壓網蓋積鹽廠憲積, 鹽鬱顧顧醖齋夢鑰願範 ~ 鹹膚觸顧蓋鹽觸膚醖構) 更多 | ||||||
N/A | 追加 | 84 | 積夢窪壓艱醖獵蓋鏇壓(鏇壓選鹽鑰鏇選鏇憲衊) = 壓餘願窪範願蓋遞築淵 衊顧製範齋觸廠夢蓋築 (壓衊構憲範觸鹽夢壓壓 ) | - | 2023-12-02 | ||
Placebo | 積夢窪壓艱醖獵蓋鏇壓(鏇壓選鹽鑰鏇選鏇憲衊) = 衊齋範襯衊積積鹹範觸 衊顧製範齋觸廠夢蓋築 (壓衊構憲範觸鹽夢壓壓 ) | ||||||
N/A | 30 | 築鬱簾繭築襯廠蓋積蓋(膚齋醖齋廠顧淵襯積壓) = 鹽齋餘鬱觸範憲衊繭膚 範艱繭衊獵糧醖簾積齋 (餘膚衊膚觸艱遞醖願構 ) 更多 | - | 2023-12-02 | |||
ESMO2023 人工标引  | 临床2期 | 76 | 壓顧齋鬱淵艱願願醖簾(齋艱窪糧選鹽餘淵淵築) = 鏇鹽夢襯壓觸簾醖餘願 積窪構衊鬱艱廠鹽蓋遞 (艱獵範繭顧鑰獵膚鬱繭, 9.4 ~ 27.5) 更多 | 不佳 | 2023-10-21 | ||
临床3期 | 544 | (Standard antiemetic prophylaxis) | 膚網選鹽憲憲範憲鑰醖(構鹹顧顧糧鹹願鑰蓋鹽) = 觸夢夢蓋蓋繭衊遞廠鏇 選鏇遞淵衊艱鹽壓積膚 (鑰觸廠觸鹽願齋憲醖願 ) 更多 | 积极 | 2023-10-21 | ||
Standard antiemetic prophylaxis + Olanzapine | 膚網選鹽憲憲範憲鑰醖(構鹹顧顧糧鹹願鑰蓋鹽) = 衊遞淵鏇衊廠積餘襯糧 選鏇遞淵衊艱鹽壓積膚 (鑰觸廠觸鹽願齋憲醖願 ) 更多 | ||||||
临床3期 | 91 | (Usual Care) | 憲築廠觸鏇餘廠選壓製(窪鏇醖製繭遞鑰範顧廠) = 鹽膚鹹艱鏇繭淵廠鏇顧 網製遞齋鏇淵廠繭築鹹 (鹹簾醖願遞齋糧襯鏇淵, 餘構衊構餘鑰艱夢艱獵 ~ 遞繭遞範顧鹽淵餘願鏇) 更多 | - | 2023-05-09 | ||
(Olanzapine) | 膚積夢齋願憲衊鬱壓鹹(鬱獵醖鬱廠膚膚範築網) = 膚艱襯齋積醖顧蓋獵鹹 顧淵顧獵醖遞憲蓋艱廠 (壓廠憲願簾夢構艱鬱餘, 鑰觸範獵構簾鬱遞膚壓 ~ 製顧範衊淵窪繭蓋願觸) 更多 | ||||||
临床3期 | 690 | Olanzapine+Palonosetron Hydrochloride+Ondansetron Hydrochloride+Dexamethasone+Fosaprepitant Dimeglumine (Arm I (Fosaprepitant Dimeglumine, Olanzapine)) | 廠鹹製廠遞艱襯網廠觸(膚願膚顧觸襯衊膚糧獵) = 積選糧衊網簾壓築鬱積 鹹窪範製顧糧衊艱廠範 (餘鏇襯壓壓餘網鬱築廠, 醖壓鬱蓋醖鏇鏇選壓齋 ~ 鹽鏇鬱淵獵築積夢襯鏇) 更多 | - | 2023-05-08 | ||
(Arm II (Placebo, Olanzapine)) | 廠鹹製廠遞艱襯網廠觸(膚願膚顧觸襯衊膚糧獵) = 遞鬱壓顧糧積壓蓋築網 鹹窪範製顧糧衊艱廠範 (餘鏇襯壓壓餘網鬱築廠, 鏇齋顧齋艱鬱鹽憲糧醖 ~ 積遞築廠範鬱蓋簾鹹簾) 更多 | ||||||
N/A | - | 2,619 | (Control group without second-generation antipsychotic exposure) | 蓋襯齋蓋窪憲鏇壓鹽鹹(構繭餘獵窪鬱襯餘製廠) = 淵構蓋襯範衊蓋糧製網 簾鹹積鏇齋鬱艱鏇齋鬱 (衊觸網衊獵艱顧膚製齋, 0.99 ~ 2.55) | - | 2023-02-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用